SV Health Investors Managing Partner Kate Bingham shares the firm's investment philosophy and gives her take on the current state of life sciences in the United Kingdom and beyond
Kate Bingham describes the type of investments SV makes, which was in the news this week for being the founding investor of the neuropsych company Draig Therapeutics that exited stealth with $140M. Plus, having previously served as the chair of the government's Vaccine Taskforce during COVID, she also shares her thoughts on the evironment in the UK and the MHRA.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.